The Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research

Background—A clear need exists for a more systematic understanding of the epidemiology, diagnosis, and management of cardiovascular diseases. More robust data are also needed on how well clinical trials are translated into contemporary community practice and the associated resource use, costs, and outcomes. Methods and Results—The National Heart, Lung, and Blood Institute recently established the Cardiovascular Research Network, which represents a new paradigm to evaluate the epidemiology, quality of care, and outcomes of cardiovascular disease and to conduct future clinical trials using a community-based model. The network includes 15 geographically distributed health plans with dedicated research centers, National Heart, Lung, and Blood Institute representatives, and an external collaboration and advisory committee. Cardiovascular research network sites bring complementary content and methodological expertise and a diverse population of ≈11 million individuals treated through various health care delivery models. Each site’s rich electronic databases (eg, sociodemographic characteristics, inpatient and outpatient diagnoses and procedures, pharmacy, laboratory, and cost data) are being mapped to create a standardized virtual data warehouse to facilitate rapid and efficient large-scale research studies. Initial projects focus on (1) hypertension recognition and management, (2) quality and outcomes of warfarin therapy, and (3) use, outcomes, and costs of implantable cardioverter defibrillators. Conclusions—The Cardiovascular Research Network represents a new paradigm in the approach to cardiovascular quality of care and outcomes research among community-based populations. Its unique ability to characterize longitudinally large, diverse populations will yield novel insights into contemporary disease and risk factor surveillance, management, outcomes, and costs. The Cardiovascular Research Network aims to become the national research partner of choice for efforts to improve the prevention, diagnosis, treatment, and outcomes of cardiovascular diseases.

[1]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[2]  Robert H Christenson,et al.  Improving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: the CRUSADE initiative. , 2002, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[3]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[4]  T. Gaziano.  Reducing the growing burden of cardiovascular disease in the developing world. , 2007, Health affairs.

[5]  Andreas Hoeft,et al.  Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. , 2005, The New England journal of medicine.

[6]  Grace Investigators,et al.  Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. , 2001, American heart journal.

[7]  L. Goldman,et al.  Report of the National Heart, Lung, and Blood Institute Working Group on Outcomes Research in Cardiovascular Disease , 2005, Circulation.

[8]  Eric Peterson,et al.  The Prospective Registry Evaluating Myocardial Infarction: Events and Recovery (PREMIER)--evaluating the impact of myocardial infarction on patient outcomes. , 2006, American heart journal.

[9]  Hugh Calkins,et al.  ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). , 2006, Circulation.

[10]  W. French.  Trends in acute myocardial infarction management: use of the National Registry ofMyocardial Infarction in quality improvement. , 2000, The American journal of cardiology.

[11]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[12]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[13]  H. Calkins,et al.  ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). , 2006, Journal of the American College of Cardiology.

[14]  H V Anderson,et al.  The American College of Cardiology-National Cardiovascular Data Registry™ (ACC-NCDR™): building a national clinical data repository , 2001 .

[15]  E. Ding,et al.  Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. , 2006, JAMA.

[16]  P. Serruys,et al.  A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[17]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[18]  Sarah M. Greene,et al.  Building a virtual cancer research organization. , 2005, Journal of the National Cancer Institute. Monographs.

[19]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[20]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[21]  L. Wilkins.  ACC/AHA/HRS 2006 Key Data Elements and Definitions for Electrophysiological Studies and Procedures , 2006 .

[22]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[23]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[24]  R Platt,et al.  Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on therapeutics , 2001, Pharmacoepidemiology and drug safety.

[25]  J. Avorn,et al.  The exclusion of the elderly and women from clinical trials in acute myocardial infarction. , 1992, JAMA.

[26]  Vincent Dor,et al.  Pioneers in cardiology: Vincent Dor, MD. Interview by Mark Nicholls. , 2007 .

[27]  A. Go,et al.  Cardiology clinical trial participation in community-based healthcare systems: obstacles and opportunities. , 2008, Contemporary Clinical Trials.

[28]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[29]  Ihab Hajjar,et al.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. , 2003, JAMA.

[30]  D. Goff,et al.  ACC/AHA 2007 methodology for the development of clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. , 2007, Journal of the American College of Cardiology.

[31]  R. Vasan,et al.  Epidemiology of uncontrolled hypertension in the United States. , 2005, Circulation.

[32]  Sarah M. Greene,et al.  The role of research in integrated healthcare systems: the HMO Research Network. , 2004, The American journal of managed care.

[33]  Johan Lindbäck,et al.  Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.

[34]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[35]  Vandana Sundaram,et al.  Quality Improvement Strategies for Hypertension Management: A Systematic Review , 2006, Medical care.

[36]  A. Garg,et al.  Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. , 2006, JAMA.

[37]  J. Hirsh,et al.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[38]  Francis S. Collins,et al.  The case for a US prospective cohort study of genes and environment , 2004, Nature.

[39]  Marc A Pfeffer,et al.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2005, The New England journal of medicine.

[40]  Ralph D'Agostino,et al.  Stent thrombosis in randomized clinical trials of drug-eluting stents. , 2007, The New England journal of medicine.

[41]  Sarah M. Greene,et al.  Building a research consortium of large health systems: the Cancer Research Network. , 2005, Journal of the National Cancer Institute. Monographs.

[42]  D. Bates,et al.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting. , 2003, JAMA.